ABSTRACT. Low-dose estrogen therapy significantly increases radioimmunoassayable serum hGH concentrations in the prepubertal hypogonadal female. In this study, we have examined the effects of short-and long-term low-dose ethinyl estradiol therapy on the endogenous production rates and metabolic clearance rates of hGH. We used deconvolution mathematical modeling to provide quantitative estimates of individual secretory parameters and to calculate subject-specific hGH metabolic clearance rates, by using all serum hGH concentrations and their variances considered simultaneously. Nine girls with Turner's syndrome (mean age 7.7 f 0.5 y) were studied on three separate nights by drawing blood every 20 min from 2200 to 0800 h before (I), after 1 wk (11), and 5 wk (111) of 100 ng/kg/d ethinyl estradiol therapy orally. We found that the endogenous hGH production rate more than doubled in all patients studied after 5 wk of ethinyl estradiol therapy was not altered in the estrogen treatment paradigm with a mean of 19 f 1.6 min in study I and 18 f 1.2 min in both studies I1 and 111. Our results suggest that even prepubertal concentrations of gonadal steroids in the hypogonadal female may be physiologically relevant to the maintenance of normal somatotrope secretory function. (Pediatr Res 28: 626-630,1990) Abbreviations EE, ethinyl estradiol GHRH, growth hormone-releasing hormone New deconvolution techniques allow the precise and valid assessment of alterations in the amplitude, duration, and frequency of pulsatile hormone secretion, which give rise to the varying plasma hormone concentration profiles. For example, a multiple parameter deconvolution model (6, 7) allows one to evaluate quantitatively the number of spontaneous hGH secretory bursts per 24 h, as well as their amplitude, frequency, duration and hGH mass secreted per burst. Thus, subject-specific production and metabolic clearance rates of endogenous hGH can be estimated with this model. However, to date, a comprehensive assessment of whether changes in hGH production and/ or clearance rates are elicited by sex steroid hormones has not been accomplished, particularly in children with gonadal failure. Our study was designed to characterize changes in hGH production and metabolic clearance rates induced by the administration of low-dose estrogen in the hypogonadal prepubertal female.
ABSTRACT. Low-dose estrogen therapy significantly increases radioimmunoassayable serum hGH concentrations in the prepubertal hypogonadal female. In this study, we have examined the effects of short-and long-term low-dose ethinyl estradiol therapy on the endogenous production rates and metabolic clearance rates of hGH. We used deconvolution mathematical modeling to provide quantitative estimates of individual secretory parameters and to calculate subject-specific hGH metabolic clearance rates, by using all serum hGH concentrations and their variances considered simultaneously. Nine girls with Turner's syndrome (mean age 7.7 f 0.5 y) were studied on three separate nights by drawing blood every 20 min from 2200 to 0800 h before (I), after 1 wk (11), and 5 wk (111) of 100 ng/kg/d ethinyl estradiol therapy orally. We found that the endogenous hGH production rate more than doubled in all patients studied after 5 wk of ethinyl estradiol therapy New deconvolution techniques allow the precise and valid assessment of alterations in the amplitude, duration, and frequency of pulsatile hormone secretion, which give rise to the varying plasma hormone concentration profiles. For example, a multiple parameter deconvolution model (6, 7) allows one to evaluate quantitatively the number of spontaneous hGH secretory bursts per 24 h, as well as their amplitude, frequency, duration and hGH mass secreted per burst. Thus, subject-specific production and metabolic clearance rates of endogenous hGH can be estimated with this model. However, to date, a comprehensive assessment of whether changes in hGH production and/ or clearance rates are elicited by sex steroid hormones has not been accomplished, particularly in children with gonadal failure. Our study was designed to characterize changes in hGH production and metabolic clearance rates induced by the administration of low-dose estrogen in the hypogonadal prepubertal female.
MATERIALS AND METHODS
Study design. Nine young girls with Turner's syndrome participated in our study after informed written consent was obtained from their parents. Our study was approved by the Jacksonville Baptist Medical Center Investigational Review Board. Seven of these nine subjects were reported previously (2) . Their ages ranged between 5.4 and 10.4 y (mean 7.7 f 0.5 y) and all had 45.XO or related karvotv~es. None had received hormonal ther-< ap; previously and all were in good health. Each patient was admitted on three separate nights to the hospital-based research unit of the Nemours Children's Clinic. At baseline a heparin lock needle was inserted in a forearm vein for frequent blood samding. From 2000 to 0800 h. blood was withdrawn at 20-min A -intervals for serum hGH determinations. Four wk after discharge, all girls were started on 100 ng/kg of EE orally daily. One wk (study 11) and 5 wk (study 111) after initiation of the lowhGH secretion is significantly influenced by sex steroid hor-dose EE therapy, the patients returned for an identical study. mones. For example, studies have shown that circulating hGH Assays. Serum hGH concentrations were measured in dupliconcentrations increase under normal physiologic circumstances cate using the Nichols Institute hGH immunoradiometric assay such as during puberty and in response to the exogenous admin-kits (San Juan Capistrano, CA). The intraassay coefficient of istration of androgens (1) . Recently, we demonstrated significant variation was 4 % with a sensitivity of 0.5 pg/L. increases in hGH concentrations after the administration of low Data analysis. The concentration of a hormone in the blood doses of estrogen to a group of hypogonadal girls with Turner's compartment at any time derives from the combined effects of syndrome (2) . Other investigators have also found a marked simultaneously occurring hormone secretion and hormone elimstimulative effect of sex steroid hormones on hGH levels (3) and ination or clearance. The secretory function (which denotes the on linear growth (4, 5) . Whether increased serum hGH levels secretory rate as a function of time) was constructed as a finite were due to increased production or decreased clearance of hGH series of discrete secretory bursts, with determinable, statistically could not be ascertained from these studies.
bounded amplitudes, half durations, and secretory times distributed randomly throughout the sampling interval (6, 7) . A distinct
Received January 22, 1990; accepted ~u l y 11, 1990. secretory burst was then defined as a random (Gaussian) distri- curve. This is illustrated algebraically as:
s (2) Integral of the secretion impulse time The elimination or clearance function was defined as a onecomponent exponential model with a subject-specific half-life of hormone elimination fitted simultaneously with the secretion parameters. This is illustrated algebraically as:
elimination function time Because these two functions (secretion and clearance) act simultaneously to influence the same system, they are said to be mathematically "convolved." The serum hormone concentration resulting from the interaction of these two processes can be then described by a convolution integral illustrated here:
Superimposed upon this are the additional effects of such unpredictable variables as assay noise and experimental error, to produce the hormone concentration profiles we observed experimentally. The process of unraveling this convolution integral to uncover and describe these two separate convolved functions is referred to as "deconvolution." We assume in this model that the distribution volume and elimination rate constants in any one subject are invariant during the particular interval of observation (8) . hGH concentrations were assumed to decay with hGH IRMA.
Estimating secretion and clearance parameters. We used a modified Gauss-Newton quadratic convergence procedure to determine the following individual parameter values and their joint statistical confidence limits: half-duration of each subject's secretory bursts; amplitudes of all secretory bursts; temporal positions of all secretory bursts; and single-component (nonexponential) subject-specific disappearance rate constants. The mass of hGH secreted per pulse is the integral (area) of the resolved secretory burst (6, 7) , and the 12-h production rate is the product of the total number of secretory bursts and the mean mass of hGH released per burst.
Previously, we have used cluster analysis (9) on the hGH concentration series to examine hormone "pulses." Using this procedure, one can estimate the frequency, amplitude, mean hormone concentration, and area under the curve of discrete hGH concentration measurements arranged by the time of the day. Secretion is not estimated by this method. Figure 1 com- The middlepanel shows a continuous curve representing hGH concentrations that would be expected to exist if the discrete pituitary episodes had occurred as predicted. This is the "reconvolution" curve, which allows the investigator to directly visualize how well the model describes the actual measured hormone concentrations. This curve provides a check on the reasonableness of the estimated parameters. In the bottom panel, the pituitary hGH secretion episodes estimated by deconvolution are illustrated graphically. Each burst is a Gaussian distribution of secretory rates and is separated from others by periods of secretory quiescence.
Statistics. Because of departures from normality, hGH secretory and clearance values were subjected to logarithmic transformation before application of Dunnett's test (10) for multiple protected comparisons with a single mean.
RESULTS
The deconvolution data for all nine patients studied are summarized in Table 1 . For comparison, the cluster analysis of the hGH series on all nine patients is provided in Table 2 . Cluster data of seven of the nine patients were previously reported (I). Deconvolution analysis provides a n estimate of the subjectspecific half-life of h G H disappearance from plasma. The halflife of endogenous h G H was not altered in the estrogen treatment paradigm with a mean of 19 + 1.6 min in study I and 18 + 1.2 min in both studies I1 and 111.
This analysis also provides a n estimate of the duration of h G H secretion associated with each secretory burst. The half-duration (time elapsing at half-maximal amplitude) of computer-detected h G H secretory bursts was stable over the two estrogen-treatment visits. (27 f 2.3 min study I versus 27 a 2.5 min study I1 and 29 + 1.2 rnin study 111).
As shown in Figure 2 , when deconvolution analysis was applied to the hGH concentration series, the frequency of the h G H secretory bursts (number of h G H secretory bursts112 h) increased after the second treatment visit (5.3 & 0.6 study I, 6.9 + 0.3 study 11, and 7.9 + 0.5 study 111). Conversely, the interpulse interval decreased on the first and second treatment visit (Fig.  3) . The mass of h G H released per secretory burst as well as the amplitude of the h G H burst (maximal rate of h G H release) increased by the third treatment visit, but the latter change did not achieve statistical significance.
The production rate of endogenous h G H can be calculated as the product of the number of h G H secretory bursts and the mass of h G H secreted per burst. Assuming a correct estimate of halflife (above), such production rates accurately reflect the effect of subject-specific metabolic clearance rates acting upon all secreted hormone molecules (4) . During the baseline study, the h G H production rate was 194 f 22 versus 290 f 43 Fg/L/ 12 h during study I1 and 412 f 66 during study I11 ( p < 0.05, Fig. 4 ).
An example of the deconvolution fitted serum h G H profiles in two patients is shown in Figures 5 and 6 , comparing the changes during the three study nights for estimated serum h G H concentrations as well as calculated h G H secretion rate. Fig. 2 . Subject-specific frequencies of pulsatile hGH secretion in nine patients with Turner's syndrome at baseline, after 1 wk (acute), and after 5 wk (chronic) of therapy with 100 ng/kg of EE orally. The 12-h hGH concentration series were collected by drawing blood at 20-min intervals through an indwelling catheter from 2000 to 0800 h and analyzed by deconvolution methods. hGH secretory burst frequencies (numbers of hGH bursts 112 h) before and after long-term therapy were statistically significant (p < 0.05). reported in girls with Turner's syndrome given low doses of estrogen (2) results from a significant increase in the hGH production rate rather than any change in hGH half-life (and therefore metabolic clearance rate) in the estrogen-enriched milieu. By deconvolution analysis, we assessed the subject-specific quantitative features of endogenous hGH secretion and metabolic clearance simultaneously, and observed that the nocturnal production rate of hGH after 5 wk of low-dose EE more than doubled in these patients.
Our previous observations (2) showed a remarkable increase in radioimmunoassayable serum hGH concentrations, with a corresponding decrease in serum FSH concentrations in a group of patients with Turner's syndrome after 1 and 5 wk of EE therapy.The previous analysis did not provide information regarding hormonal clearance and secretion. Deconvolution analysis on the other hand, allows the estimation of both secretory and clearance parameters. Therefore, the apparent increase in the frequency of hGH bursts appears to be accounted for by a better delineation of the hGH secretory event per se, in which deconvolution analysis was able to identify "pulses within pulses" of hGH activity. As can be seen in the reconvolution curves, they very closely approximate the known hGH concentrations of these patients. Similar approximations were obtained in all data sets. The additional deconvolution results shown in Figures  5 and 6 do not illustrate actual measured hGH concentrations, but rather estimated hGH secretory events (bursts).
The subject-specific half-lives of plasma hGH disappearance did not change during low-dose estrogen therapy. Specifically, the calculated half-life of endogenous hGH was 19 min before and 18 min after both estrogen treatment visits. These estimates are indistinguishable from those reported for endogenous hGH in normal men, whose hGH disappearance kinetics were investigated by the consecutive administration of hGH-releasing hormone and somatostatin (1 I). This failure of steroids to modify hGH metabolic clearance in vivo is important to note in view of the recent finding that hGH clearance rates can change under other conditions (12) .
The precise neuroendocrine mechanisms subserving an increased hGH production rate after therapy with low doses of estrogen are not known, but the marked augmentation of the hGH secretory rate suggests a significant enhancement of somatotrope responsiveness to GHRH action and/or increased GHRH release. Such effects could be secondary to direct facilitative actions of low-dose estrogen on the somatotrope, decreased somatostatin inhibitory tone, and/or amplified GHRH pulse generation. Facilitation of GHRH action could elicit measureable increases in hGH secretion, which might otherwise have been undetectable, therefore causing an evident change in pulse frequency.
In conclusion, because even very low doses of estrogen can amplify pulsatile hGH secretion selectively without altering the hGH clearance, our data support the concept that prepubertal concentrations of gonadal steroids in the female may be important for the maintenance of normal somatotrope secretory function.
